Progress of etiology and immunotherapy of dilated cardiomyopathy
SHEN Qiming1 WANG Hui1 ZHANG Jianzhong1 MA Lihong2 ZHANG Yihong3▲
1.Department of Cardiology,Linyi Hospital of Traditional Chinese Medicine,Shandong Province,Linyi 276000,China;
2.Department of Traditional Chinese Medicine,Fuwai Hospital,Beijing 100032,China;3.Department of Intensive Care Medicine,Linyi People's Hospital,Shandong Province,Linyi 276000,China
Abstract：Dilated cardiomyopathy (DCM) is a disease that seriously endangers human health.It is characterized by left ventricular systolic dysfunction and left ventricular enlargement,with a high incidence rate and poor prognosis.The pathogenesis of DCM is multifactorial,including genetic and acquired factors.Genetic factors mainly refer to gene mutations,with Titin(TTN)gene mutations and Lamin AC(LMNA)gene mutations being the most common types of mutations in the genetic etiology of DCM.Acquired factors include infection,alcohol,and immune mediation.Existing research has shown that viral infection and immune response cause myocardial damage and produce anti automyocardial antibodies,which play an important role in the occurrence and development of DCM.Specific treatment for related causes has gradually become one of the research hotspots.On the basis of conventional treatment methods such as diuresis,vasodilation,and delayed ventricular remodeling,immunotherapy can be used to remove anti myocardial antibodies from patients with positive anti myocardial antibodies,which can reduce myocarditis in patients with dilated cardiomyopathy,improve heart function,and prognosis.However,currently immunotherapy lacks evidence from large-scale clinical trials to support it,and is only an experimental treatment option for DCM patients.
Pinto YM，Elliott PM，Arbustini E，et al.Proposal for a revised definition of dilated cardiomyopathy，hypokinetic non-dilated cardiomyopathy，and its implications for clinical practice：a position statement of the ESC working group on myocardial and pericardial diseases[J].Eur Heart J，2016，37（23）：1850-1858.
Heymans S，Lakdawala NK，Tschope C，et al.Dilated cardiomyopathy：causes，mechanisms，and current and future treatment approaches[J].Lancet，2023，402（10406）：998-1011.
[4]
Sinagra G，Elliott PM，Merlo M.Dilated cardiomyopathy：so many cardiomyopathies[J].Eur Heart J，2020，41（39）：3784-3786.
[5]
Arbustini E，Morbini P，Pilotto A，et al.Genetics of idiopathic dilated cardiomyopathy[J].Herz，2000，25（3）：156-160.
[6]
Pinto YM，Creemers EE，Wilde AA.Heart failure：advances through genomics[J].Nat Rev Genet，2011，12（5）：357-362.
[7]
Pasotti M，Klersy C，Pilotto A，et al.Long-term outcome and risk stratification in dilated cardiolaminopathies[J].J Am Coll Cardiol，2008，52（15）：1250-1260.
Richardson P，McKenna W，Bristow M，et al.Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies[J].Circulation，1996，93（5）：841-842.
[10]
Maron BJ，Towbin JA，Thiene G，et al.Contemporary definitions and classification of the cardiomyopathies：an American Heart Association Scientific Statement from the Council on Clinical Cardiology，Heart Failure and Transplantation Committee；Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups；and Council on Epidemiology and Prevention[J].Circulation，2006，113（14）：1807-1816.
[11]
Seferovic PM，Polovina M，Bauersachs J，et al.Heart failure in cardiomyopathies：a position paper from the Heart Failure Association of the European Society of Cardiology[J].Eur J Heart Fail，2019，21（5）：553-576.
[12]
Bozkurt B，Colvin M，Cook J，et al.Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies：A Scientific Statement From the American Heart Association[J].Circulation，2016，134（23）：e579-e646.
[13]
Gulati A，Jabbour A，Ismail TF，et al.Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy [J].JAMA，2013，309（9）：896-908.
Hershberger RE，Siegfried JD.Update 2011：Clinical and Genetic Issues in Familial Dilated Cardiomyopathy[J].J Am Coll Cardiol，2011，57（16）：1641-1649.
[16]
Goldberger JJ，Subacius H，Patel T，et al.Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy[J].J Am Coll Cardiol，2014，63（18）：1879-1889.
Lewis NC，Messinger L，Monteleone B，et al.Effect of acute hypoxia on regional cerebral blood flow：effect of sympathetic nerve activity[J].J Appl Physiol（1985），2014，116（9）：1189-1196.
[19]
Gerull B，Gramlich M，Atherton J，et al.Mutations of TTN，encoding the giant muscle filament titin，cause familial dilated cardiomyopathy[J].Nat Genet，2002，30（2）：201-204.
[20]
van den Berg MP，van Spaendonck-Zwarts KY，van Veldhuisen DJ，et al.Familial dilated cardiomyopathy：another risk factor for anthracycline-induced cardiotoxicity?[J].Eur J Heart Fail，2010，12（12）：1297-1299.
[21]
Fabre A，Sheppard MN.Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death [J].Heart，2006，92（3）：316-320.
[22]
D'Ambrosio A，Patti G，Manzoli A，et al.The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy：a review[J].Heart，2001，85（5）：499-504.
[23]
Monda E，Palmiero G，Rubino M，et al.Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies[J].Int J Mol Sci，2020，21（18）：6462.
[24]
Kaya Z，Katus HA，Rose NR.Cardiac troponins and autoimmunity：their role in the pathogenesis of myocarditis and of heart failure[J].Clin Immunol，2010，134（1）：80-88.
[25]
Kühl U，Pauschinger M，Noutsias M，et al.High prevalence of viral genomes and multiple viral infections in the myocardium of adults with“idiopathic”left ventricular dysfunction[J].Circulation，2005，111（7）：887-893.
Mirijello A，Tarli C，Vassallo GA，et al.Alcoholic cardiomyopathy：What is known and what is not known[J].Eur J Intern Med，2017，43：1-5.
[30]
Fernández-Solà J.The Effects of Ethanol on the Heart：Alcoholic Cardiomyopathy[J].Nutrients，2020，12（2）：572.
[31]
Haggerty CM，Damrauer SM，Levin MG，et al.Genomics-First Evaluation of Heart Disease Associated with Titin-Truncating Variants[J].Circulation，2019，140（1）：42-54.
[32]
McMurrayJJ，PackerM，DesaiAS，et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med，2014，371（11）：993-1004.
[33]
Wallukat G，Reinke P，Dorffel WV，et al.Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption[J].Int J Cardiol，1996，54（2）：191-195.
[34]
Müller J，Wallukat G，Dandel M，et al.Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy[J].Circulation，2000，101（4）：385-391.
[35]
Weinmann K，Werner J，Koenig W，et al.Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure-A Single Center Experience[J].Biomolecules，2018，8（4）：133.
京公网安备 11010502046607号